Literature DB >> 8975915

Developmental differences determine larval susceptibility to nitric oxide-mediated killing in a murine model of vaccination against Schistosoma mansoni.

S F Ahmed1, I P Oswald, P Caspar, S Hieny, L Keefer, A Sher, S L James.   

Abstract

A persistent paradox in our understanding of protective immunity against Schistosoma mansoni infection in animals vaccinated with attenuated parasites has been that attrition of challenge parasites occurs during migration through the lungs in vivo, although parasites recovered from the lungs appear to be relatively resistant to cytotoxic effector mechanisms in vitro. We have compared the susceptibilities of different stages of larvae to killing by nitric oxide (NO), which was previously shown to be involved in the larvicidal function of cytokine-activated cytotoxic effector cells. Lung-stage larvae obtained 1 week after infection were not killed in vitro by NO generated either by a chemical NO donor or by activated cells. In contrast, parasites obtained from the portal system of control mice or from the lungs of vaccinated mice 2.5 weeks following challenge infection were killed by NO. As previously shown for mammalian cell targets, the effects of NO in susceptible larval stages may involve enzymes required for aerobic energy metabolism, since similar cytotoxicity was demonstrated by chemical inhibitors of the citric acid cycle or mitochondrial respiration. Taken together with previous observations of enhanced Th1 activity and expression of NO synthase in the lungs of vaccinated mice at 2.5 weeks after challenge infection, these observations elucidate the immune mechanism of vaccine-induced resistance to S. mansoni infection. Moreover, they suggest that conversion to a less metabolically active state may allow pathogens to escape the effects of the important effector molecule NO.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8975915      PMCID: PMC174579          DOI: 10.1128/iai.65.1.219-226.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  Experimental models of immunization against schistosomes: lessons for vaccine development.

Authors:  S L James
Journal:  Immunol Invest       Date:  1992-08       Impact factor: 3.657

2.  Elevated expression of Th1 cytokines and nitric oxide synthase in the lungs of vaccinated mice after challenge infection with Schistosoma mansoni.

Authors:  T A Wynn; I P Oswald; I A Eltoum; P Caspar; C J Lowenstein; F A Lewis; S L James; A Sher
Journal:  J Immunol       Date:  1994-12-01       Impact factor: 5.422

3.  The infection of laboratory hosts with cercariae of Schistosoma mansoni and the recovery of the adult worms.

Authors:  S R Smithers; R J Terry
Journal:  Parasitology       Date:  1965-11       Impact factor: 3.234

Review 4.  Immune effector role of macrophages in experimental schistosomiasis mansoni.

Authors:  S L James; D L Boros
Journal:  Immunol Ser       Date:  1994

Review 5.  Antiparasitic effects of nitric oxide in an in vitro murine model of Chlamydia trachomatis infection and an in vivo murine model of Leishmania major infection.

Authors:  M L Woods; J Mayer; T G Evans; J B Hibbs
Journal:  Immunol Ser       Date:  1994

6.  How anthelmintics help us to understand helminths.

Authors:  H Vanden Bossche
Journal:  Parasitology       Date:  1985-04       Impact factor: 3.234

7.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.

Authors:  J S Beckman; T W Beckman; J Chen; P A Marshall; B A Freeman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

8.  Nitric oxide (NO) donor molecules: effect of NO release rate on vascular smooth muscle cell proliferation in vitro.

Authors:  D L Mooradian; T C Hutsell; L K Keefer
Journal:  J Cardiovasc Pharmacol       Date:  1995-04       Impact factor: 3.105

9.  Post lung-stage schistosomula of Schistosoma mansoni exhibit transient susceptibility to macrophage-mediated cytotoxicity in vitro that may relate to late phase killing in vivo.

Authors:  E J Pearce; S L James
Journal:  Parasite Immunol       Date:  1986-09       Impact factor: 2.280

10.  Reduced replication of Toxoplasma gondii is necessary for induction of bradyzoite-specific antigens: a possible role for nitric oxide in triggering stage conversion.

Authors:  W Bohne; J Heesemann; U Gross
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

View more
  25 in total

1.  Biological and immunological activity of new imidazolidines against adult worms of Schistosoma mansoni.

Authors:  Juliana Kelle de Andrade Lemoine Neves; Sandra Paula Sarinho Botelho; Cristiane Moutinho Lagos de Melo; Valéria Rêgo Alves Pereira; Maria do Carmo Alves de Lima; Ivan da Rocha Pitta; Mônica Camelo Pessoa de Azevedo Albuquerque; Suely Lins Galdino
Journal:  Parasitol Res       Date:  2010-05-04       Impact factor: 2.289

2.  Nitric oxide contributes to host resistance against experimental Taenia crassiceps cysticercosis.

Authors:  Javier Alonso-Trujillo; Irma Rivera-Montoya; Miriam Rodríguez-Sosa; Luis I Terrazas
Journal:  Parasitol Res       Date:  2007-01-06       Impact factor: 2.289

Review 3.  Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity.

Authors:  F C Fang
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

4.  Cytostatic and cytotoxic effects of activated macrophages and nitric oxide donors on Brugia malayi.

Authors:  G R Thomas; M McCrossan; M E Selkirk
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

5.  Exosome-like vesicles derived by Schistosoma japonicum adult worms mediates M1 type immune- activity of macrophage.

Authors:  Lifu Wang; Zhitao Li; Jia Shen; Zhen Liu; Jinyi Liang; Xiaoying Wu; Xi Sun; Zhongdao Wu
Journal:  Parasitol Res       Date:  2015-02-19       Impact factor: 2.289

6.  Toxoplasma gondii GRA15II effector-induced M1 cells ameliorate liver fibrosis in mice infected with Schistosomiasis japonica.

Authors:  Yuanyuan Xie; Huiqin Wen; Ke Yan; Shushu Wang; Xuesong Wang; Jian Chen; Yuanling Li; Yuanhong Xu; Zhengrong Zhong; Jilong Shen; Deyong Chu
Journal:  Cell Mol Immunol       Date:  2016-05-09       Impact factor: 11.530

7.  Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the adult worm stage.

Authors:  Rosemary M Cook; Claudia Carvalho-Queiroz; Gregory Wilding; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Blood fluke exploitation of non-cognate CD4+ T cell help to facilitate parasite development.

Authors:  Erika W Lamb; Colleen D Walls; John T Pesce; Diana K Riner; Sean K Maynard; Emily T Crow; Thomas A Wynn; Brian C Schaefer; Stephen J Davies
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

9.  A STAT4-dependent Th1 response is required for resistance to the helminth parasite Taenia crassiceps.

Authors:  Miriam Rodríguez-Sosa; Rafael Saavedra; Eda P Tenorio; Lucia E Rosas; Abhay R Satoskar; Luis I Terrazas
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Role of antibody dependent cell mediated cytotoxicity (ADCC) in Sm-p80-mediated protection against Schistosoma mansoni.

Authors:  Workineh Torben; Gul Ahmad; Weidong Zhang; Stewart Nash; Loc Le; Souvik Karmakar; Afzal A Siddiqui
Journal:  Vaccine       Date:  2012-09-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.